Search

Displaying results 4481 - 4490 of 7452 in total
  1. Drug

    BRG01

    go.drugbank.com/drugs/DB18173
    Investigational

    BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]

  2. Drug

    CTR-107

    go.drugbank.com/drugs/DB18583
    Experimental

    It is being investigated for the treatment of familial exudative vitreoretinopathy.

  3. Drug

    Elebsiran

    go.drugbank.com/drugs/DB19018
    Investigational

    Elebsiran is under investigation in clinical trial NCT05461170 (SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.).

  4. Drug

    Olorofim

    go.drugbank.com/drugs/DB15245
    Investigational

    Olorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).

  5. Drug

    Centhaquine

    go.drugbank.com/drugs/DB16122
    Investigational

    Centhaquine is under investigation in clinical trial NCT04045327 (Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock).

  6. Drug

    Cicletanine

    go.drugbank.com/drugs/DB12766
    Investigational

    Cicletanine is under investigation for the treatment of Diabetes, Hypokalemia, Hyponatremia, and Arterial Hypertension.

  7. Drug

    GSK-1004723

    go.drugbank.com/drugs/DB12806
    Investigational

    Gsk1004723 has been investigated for the treatment of Allergic Rhinitis and Rhinitis, Allergic, Seasonal.

  8. Drug

    Corticorelin acetate

    go.drugbank.com/drugs/DB12915
    Investigational

    Corticorelin acetate has been investigated for the treatment of Brain Edema and Brain Tumor.

  9. Drug

    Nepicastat

    go.drugbank.com/drugs/DB12979
    Investigational

    Nepicastat has been investigated for the treatment of Cocaine Dependence and Posttraumatic Stress Disorder.

  10. Drug

    Peptide YY (3-36)

    go.drugbank.com/drugs/DB05004
    Investigational

    Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.